RxDoctor Payments DataLook up a doctor →

Benjamin Marcum, MD

Family Medicine · Stephenville, TXNPI 1588892004

Payments from drug & device makers

$7,010,482in general payments, 2019–2025

Across 1,632 payments — averaging $4295.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2.9M
  • Boehringer Ingelheim$958K
  • Pfizer$740K
  • Alnylam Pharmaceuticals Inc.$700K
  • Novartis$628K
  • Organon$443K
  • plus $676K from 42 others
$1,876in research payments, 2019–2025

Across 9 payments — averaging $208.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$2K

What the payments were for

  • Travel & lodging$1,08918%
  • Food & beverage$4,86682%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,010,482 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$214,340
Medicare patients
307
Services billed
6,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$170,232
JardianceEmpagliflozin113$154,639
OzempicSemaglutide119$147,459
EliquisApixaban189$102,157
IngrezzaValbenazine Tosylate12$91,997
MyrbetriqMirabegron65$53,335
JanuviaSitagliptin Phosphate46$50,410
FarxigaDapagliflozin Propanediol47$50,305
LinzessLinaclotide55$46,623
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog62$24,350
TrulicityDulaglutide19$19,637
RexultiBrexpiprazole13$19,183
NuedextaDextromethorphan Hbr/Quinidine11$18,887
Tadalafil13$16,886
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$16,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$58$189,869145 claims
Novo NordiskOzempic, Rybelsus$433$162,326134 claims
Boehringer IngelheimJardiance$957,702$154,639113 claims
PfizerEliquis, Premarin$739,909$108,899203 claims
Neurocrine Biosciences, Inc.Ingrezza$17$91,99712 claims
AstraZenecaFarxiga, Breztri Aerosphere$66,538$66,56563 claims
MerckJanuvia, Dulera$14$58,54460 claims
Astellas Pharma US IncMyrbetriq$229$53,33565 claims
AbbVieLinzess, Synthroid$389$49,44197 claims
Otsuka America Pharmaceutical, Inc.Rexulti$271$19,18313 claims
GSKTrelegy Ellipta$46,594$14,47315 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$64$11,51512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Stephenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →